Cooverexpression or coamplification of Grb7 and the ERBB family has been clinically investigated in human breast cancers [62,63], cervical cancers [49], invasive Barrett’s carcinoma [64], advanced esophageal carcinoma [61], and gastric cancers [10,65]. Here, GRB7 is linked to gastric cancer.